Human iPS-Cardiac-Endothelial-Tumor-on-a-Chip to Assess Anti-Cancer Efficacy and Cardiotoxicity.
Cancer remains a leading health threat in the U.S., and cardiovascular drug toxicity is a primary cause to eliminate a drug from FDA approval. As a result, the demand to develop new anti-cancer drugs without cardiovascular toxicity is high. Human induced pluripotent stem (iPS) cell-derived "tissue chips" provide potentially a cost-effective preclinical drug testing platform including potential avenues for personalized medicine. We have developed a three-dimensional microfluidic device that simultaneously cultures tumor cell spheroids with iPS-derived cardiomyocytes (iPS-CMs) and iPS-derived endothelial cells (iPS-EC). The iPS-derived cells include a GCaMP6 fluorescence reporter to allow real-time imaging to monitor intracellular calcium transients. The multiple-chambered tissue chip features electrodes for pacing of the cardiac tissue to assess cardiomyocyte function such as the maximum capture rate and conduction velocity. We measured the inhibition concentration (IC50) of the anti-cancer drugs Doxorubicin (0.1 μM) and Oxaliplatin (4.2 μM) on the tissue chip loaded with colon cancer cells (SW620). We simultaneously evaluated the cardiotoxicity of these anti-cancer drugs by assessing the drug effect on the spontaneous beat frequency and conduction velocity of iPS-derived cardiac tissue. Consistent with in vivo observations, Doxorubicin reduced the spontaneous beating rate and maximum capture rate at or near the IC50 (0.04 and 0.22 μM, respectively), while the toxicity of Oxaliplatin was only observed at concentrations beyond the IC50 (33 and 9.9 μM, respectively). Our platform demonstrates the feasibility to simultaneously assess cardiac toxicity and anti-tumor effects of drugs and could be used to enhance personalized drug testing safety and efficacy.